Clincosm LogoSign in Get a demo

Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma

Sponsor
Peking Union Medical College Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05822453
Collaborator
(none)
20
Enrollment
1
Location
1
Arm
36
Anticipated Duration (Months)
0.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study will evaluate the efficacy and safety of 1st line therapy with gemcitabine plus S1 and tislelizumab in participants with advanced biliary tract carcinoma (BTC).

Condition or Disease Intervention/Treatment Phase
Phase 2

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma (BTC): a Single Arm, Prospective, Interventional Clinical Study
Anticipated Study Start Date :
Apr 30, 2023
Anticipated Primary Completion Date :
Apr 30, 2025
Anticipated Study Completion Date :
Apr 30, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Gemcitabine plus S1 and tislelizumab

Participants will receive gemcitabine plus S1 and tislelizumab until disease progression or unacceptable toxicity

Drug: Gemcitabine
Gemcitabine (1000 mg/m2) will be administered by IV infusion on Day 1and Day 8 of each 21-day cycle

Drug: S1
S1 (60 mg/day if body surface area < 1.25 m2, 80 mg/day if body surface area = 1.25~1.50 m2) will be administered by PO on Day 1 ~ 14 of each 21-day cycle

Drug: Tislelizumab
Tislelizumab (200 mg) will be administered by IV infusion on Day 1 of each 21-day cycle

Outcome Measures

Primary Outcome Measures

  1. Objective response rate (ORR) [Baseline up to approximately 6 months]

Secondary Outcome Measures

  1. Progression free survival (PFS) [baseline up to approximately 12 months]

  2. 1-year survival rate [baseline up to approximately 12 months]

  3. Disease control rate (DCR) [baseline up to approximately 6 months]

  4. Duration of response (DoR) [baseline up to approximately 12 months]

  5. Percentage of participants with SD ≥ 4 weeks [baseline up to approximately 6 months]

  6. 3-month progression free survival rate [baseline up to approximately 3 months]

  7. 6-month progression free survival rate [baseline up to approximately 6 months]

  8. 6-month overall survival rate [baseline up to approximately 6 months]

  9. 12-month overall survival rate [baseline up to approximately 12 months]

  10. Quality of life (QoL) [baseline up to approximately 12 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
    1. Age ≤ 18 years old ≤ 75 years old, regardless of gender.
    1. Diagnosed as malignant tumor of biliary tract by histopathology or cytology, including intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, common bile duct carcinoma or gallbladder carcinoma.
    1. The disease is not suitable for radical surgery and/or local treatment;
    1. At least one measurable lesion according to RECIST 1.1 standard
    1. The ECOG score is 0-1
    1. The expected survival ≥ 12 weeks.
    1. The Child-Pugh score is 5-7
    1. Within the past 2 years, there was no active autoimmune diseases that require systemic treatment, replacement therapy (such as thyroid hormone, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary dysfunction)
    1. Women with fertility: agree to abstain during treatment and at least 6 months after the last dose (to avoid heterosexual intercourse) or use contraceptive methods with an annual contraceptive failure rate of less than 1%.
    1. Male: Agree to abstain (not engage in heterosexual intercourse) or use contraception, agree not to donate sperm
    1. The subjects voluntarily participated in the study and agreed to sign written informed consent, with good compliance and cooperation in follow-up.
Exclusion Criteria:
    1. who have any of the following: (1) suitable for surgical radical treatment, (2) have undergone radical surgery without assessable lesions, (3) have received first-line systemic treatment
    1. Known to be allergic or intolerant to recombinant humanized PD-1 monoclonal antibody drugs and their components.
    1. ECOG PS ≥ 2
    1. metastasis site>2 organs
    1. Pregnant or lactating women
    1. Received local anti-tumor therapy within 4 weeks prior to the first study drug treatment, including but not limited to radiotherapy, radiofrequency ablation, cryoablation, or percutaneous ethanol injection
    1. Receiving approved or developing systemic anticancer therapies, including chemotherapy, biological immunotherapy, targeted therapy, or Chinese herbal therapy with clear indications for anti-tumor effects
    1. There are multiple factors that can affect the oral administration of S1 (such as inability to swallow, chronic diarrhea, intestinal obstruction, or other conditions that significantly affect drug administration and absorption)
    1. Simultaneously participating in another clinical study
    1. After comprehensive assessment of the condition by the investigators, it is deemed unsuitable to participate in this study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Chinese Academy of Medical Sciences & Peking Union Medical College Hospital Beijing China

Sponsors and Collaborators

  • Peking Union Medical College Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Peking Union Medical College Hospital
ClinicalTrials.gov Identifier:
NCT05822453
Other Study ID Numbers:
  • BTC-001
First Posted:
Apr 20, 2023
Last Update Posted:
Apr 20, 2023
Last Verified:
Apr 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Carcinoma
Gemcitabine

Study Results

No Results Posted as of Apr 20, 2023